The mailings killed 5 people as good as unprotected hundreds some-more – with thousands of US adults looking preventative antibiotics. Since afterwards a biodefense attention has grown massively, with a US releasing around $50bn in biodefence appropriation in 2001-2009. Other general bodies, such as a EU, have additionally increasing their commitment as good as investigate efforts.
This inform sets out to inform as good as investigate a work of a biodefense attention in conditions of past, benefaction as good as destiny curative research, expansion as good as prolongation to opposite or yield diseases caused by biological attack. It additionally will inform supervision policies as good as initiatives in multiform countries which have spurred investigate as good as prolongation in curative countermeasures as good as treatments for such diseases as good as will inspect a assorted factors which change those policies as good as a market, together with stream as good as destiny threats as good as how a attention is responding to latest discoveries.
Scope of this report
• •Analysis of supervision appropriation levels in a US as good as Europe as good as inform upon stream grants accessible for biodefense research.
• •Estimation of biodefense in a US for 2010 as good as foresee sum to 2012.
• •In-depth investigate of a vital biodefense firms handling in a US, Europe, Australia as good as Canada as good as good as those handling in rising markets such as China, India as good as Israel.
• • Analysis of a vital hazard areas in a biodefense marketplace together with – anthrax, plague, tularemia, tiny pox viral hemorrhagic fevers, botulism, ricin, staphylococcal enterotoxins, brucella, glanders, melioidosis as good as Q fever.
Key commentary from this report
• •The US is pushing a attention as good as sum biodefense appropriation in in between 2001-2009 reached $49.6bn. However, expansion is set to delayed significantly in a entrance years as all Project BioShield appropriation has right away released.
• •However, a singular critical bioterrorist situation in a US could coax an additional turn of supervision spending as happened after a 2001 anthrax attacks. Recent threats such as pestilence hog influenza have been additionally forcing governments to cruise a origination of vast stockpiles of healing countermeasure.
• •The stream mercantile predicament could be generally critical for a biodefense industry. As most of a active participants have been small-scale as good as reliant upon outward appropriation to say operations, marked down credit options could force them out of business
Key issues
• Since 2001 US appropriation for Biodefense has reached $49.6bn. The rise year for spending was 2005, due to a vast distribution of supports from Project BioShield, however 2009 was additionally witnessed clever investment.
• In 2010, Business Insights estimates which sum biodefense appropriation in a US will strech $5,932mn. If we were to take BioShield appropriation out of a sum for 2009, afterwards 2010 represented expansion of 1.4% (year-on-year), a annulment of a direction seen in in between 2006-2008.
• There have usually been a tiny series of bioterrorist incidents in a past thirty years, with a series of fatalities superfluous limited. But due in partial to a mental fright combined by these weapons, a US military, in particular, has invested heavily in scheming vaccines as good as therapeutics.
• The monument of bioterrorist attacks, due to a impassioned worry in weaponizing as good as delivering biological agents, has caused countless systematic groups to impugn a stream tall spending levels upon investigate in to healing opposite measures.
Use this inform to:
• What have been a vital trends pushing a biodefense market?
• What is a stream state of R&D in a biodefense market?
• How has a regulatory pathway altered in new years, as good as how is this fulfilment attention development?
• What have been a stream appropriation levels for biodefense as good as what is a foresee 2010-2012?
• Which product areas yield a biggest event for destiny development?
Table of Contents :
Table of Contents
The Future of a Biodefense Industry
Executive outline 12
Setting a stage 12
Regulatory sourroundings 13
Major pathogens for BW 14
Biodefense appropriation 15
Company profiles 16
Future perspectives 17
Chapter 1 Setting a stage 20
Summary 20
Introduction 21
The operate of biological agents in crusade as good as terrorism 22
Warfare 22
Offensive BW programs 23
Bioterrorism: Extent as good as inlet of a hazard 24
Creation 26
Bulk make 27
Weaponization 27
Delivery 27
Future threats 29
Pre-2001 bioterrorism 29
2001 – Sep eleven as good as a anthrax attacks 30
Chapter 2 Regulatory sourroundings 34
Summary 34
Introduction 35
US bodies 36
FDA 38
Center for Biologics Evaluation as good as Research (CBER) 38
Center for Drug Evaluation as good as Research (CDER) 40
Office of Counterterrorism as good as Emerging Threats 41
National Institutes of Health (NIH) 41
The National Institute of Allergy as good as Infectious Diseases (NIAID) 42
Biomedical Advanced Research as good as Development Authority
(BARDA) 43
Public Health Emergency Medical Countermeasures Enterprise
(PHEMCE) 44
Project Bioshield 45
Centers for Disease Control as good as Prevention (CDC) 48
US Army Medical Materiel Development Activity (USAMMDA) 49
European bodies 49
European Commission 50
European Council Health Security Committee 51
European Centre for Disease Prevention as good as Control (ECDC) 54
The European Medicines Agency (EMEA) 55
Economic Commission for Europe 57
Joint Commission/Pharmaceutical Industry Task Force 57
2009-2011 Indicative Program for a Instrument for Stability 58
International Agencies 58
World Health Organisation (WHO) 58
United Nations 59
Global Health Security Initiative (GHSI) 59
Chapter 3 Major pathogens for BW 62
Summary 62
Introduction 63
Anthrax 64
Developmental therapeutics as good as vaccines 65
Plague 68
Developmental therapeutics as good as vaccines 69
Tularemia 70
Developmental therapeutics as good as vaccines 70
Smallpox 71
Developmental therapeutics as good as vaccines 72
Viral Hemorrhagic Fevers – Ebola, Marburg, Crimean-Congo, Hantavirus, Lassa 74
Developmental therapeutics as good as vaccines 75
Botulism 77
Developmental therapeutics as good as vaccines 77
Ricin 79
Developmental therapeutics as good as vaccines 80
Staphylococcal enterotoxins 81
Developmental therapeutics as good as vaccines 81
Brucella organisation 82
Developmental therapeutics as good as vaccines 82
Glanders 83
Developmental therapeutics as good as vaccines 83
Melioidosis (Whitmore’s disease) 84
Developmental therapeutics as good as vaccines 84
Q heat 85
Developmental therapeutics as good as vaccines 86
Conclusion 87
Chapter 4 Biodefense appropriation 90
Summary 90
US appropriation 91
Department of Health as good as Human Services (HHS) 93
Biomedical Research as good as Development Authority (BARDA) 94
Department of Homeland Security (DHS) 96
Other departments 97
Grants accessible for biodefense R&D in a US 97
NIH Challenge grants in illness & scholarship investigate 98
NIH Cooperative Research & Development Agreement (CRADA) 98
Small commercial operation awards 99
NIH tiny commercial operation biodefense module awards 100
Project BioShield awards 101
Regional Centers of Excellence for Biodefense as good as Emerging
Infectious Diseases (RCE) 102
Defense Threat Reduction Agency (DTRA) 103
US Army Medical Research Institute of Infectious Diseases (USAMRIID) 103
Technology send 103
Defense Advanced Research Projects Agency (DARPA) 104
European appropriation 104
United Kingdom 105
France 106
Germany 106
EU biodefense programs 107
European Defense Agency (EDA) 107
EDA’s Joint R&D Investment Program 107
Bio-Edep 108
Bioterrorism Research Resilience Reaction (BIO3R) 108
Biodefense attention 108
New as good as Emerging Science as good as Technology (NEST) 109
Health Protection Agency (HPA) 110
Defense Science as good as Technology Laboratory (Dstl) 110
Japan 111
Chapter 5 Company profiles 114
Summary 114
Introduction 115
US 117
Achaogen 117
Contracts 118
Advanced Life Sciences 118
Contracts 119
Alnylam Pharmaceuticals 119
Contracts 119
Cleveland BioLabs 120
Contracts 120
Dynavax Technologies Inc. 121
Contracts 121
Dynport Vaccine Company Llc (DVC) 122
Contracts 122
Elusys Therapeutics 122
Contracts 123
Emergent BioSolutions 123
Contracts 125
Ichor Medical Systems 126
Contracts 126
Nanotherapeutics 127
Contracts 127
Peregrine Pharmaceuticals, Inc. 127
Contracts 128
PharmAthene 128
Contracts 129
SIGA Technologies 130
Contracts 131
VaxGen 132
Contracts 132
XOMA 132
Contracts 132
Canada 133
Affinium Pharmaceuticals 133
Contracts 133
Cangene 133
Contracts 135
ID Biomedical Corporation 135
Contracts 136
UK 136
Acambis 136
Contracts 137
Cambridge Biostability (CBL) 137
Contracts 138
MNLpharma 138
Contracts 138
Denmark 139
Bavarian Nordic 139
Contracts 140
Australia 141
Vaxine Pty 141
Contracts 141
India 141
Panacea Biotec Ltd. 142
Contracts 142
China 143
Sinovac Biotech Ltd. 144
Israel 144
Medison Pharma 145
Conclusion 145
Biodefense products: a risks 147
Chapter 6 Future perspectives 152
Summary 152
Introduction 153
Assessing destiny threats 153
GM record 154
Synthetic biology 156
US appropriation – a being 157
Has a US got worth for a £50 billion-worth of appropriation given 2001? 159
Potential biodefense commercial operation 159
Getting a accede to in a US 160
Project Bioshield 161
Is Europe you do enough? 162
Lack of coordination 164
US 164
EU 165
Biodefense – during a responsibility of alternative research? 166
Mismanagement of a save 167
Case study: VaxGen 167
Problems of biosecurity 169
US 169
Russia as good as a FSU 171
Fulfilling unmet needs 172
Conclusion 173
Chapter 7 Appendix 176
CDC characterization of biological threats 176
Glossary 177
Index 181
List of Figures
Figure 1.1: Bioterrorism incidents 1970-2008 26
Figure 2.1: US biodefense appropriation by dialect 2001-09 37
Figure 3.1: R&D appropriation pathway for biodefense healing countermeasures 43
Figure 4.1: Project BioShield buying routine 46
Figure 4.5: US biodefense appropriation ($m), 2001-12 93
Figure 4.6: BARDA appropriation forecasts ($m), 2009-14 96
Figure 5.7: Cleveland BioLabs investigate spending upon Protectan CBL502 for biodefense applications ($m), 2008-09 121
Figure 5.8: Emergent BioSolutions handling formula ($m), 2008-09 125
Figure 5.9: PharmAthene monetary formula ($m), 2008-09 130
Figure 5.10: Cangene monetary formula ($m), 2004-08 134
Figure 5.11: Bavarian Nordic financials (DKKm), 2004-08 140
Figure 6.12: US biodefense appropriation ($m), 2001-09 158
Figure 6.13: VaxGen financials ($m), 2005-08 168
Figure 6.14: NIH saved biocontainment laboratories 170
Figure 7.15: CDC characterization of biological threats 176
List of Tables
Table 2.1: US biodefense presidential acts 40
Table 2.2: US biodefense acts post-2001 48
Table 2.3: European Biodefense Legislation 54
Table 3.4: Developmental therapeutics as good as vaccines for anthrax 66
Table 3.5: Developmental therapeutics as good as vaccines for mildew 69
Table 3.6: Developmental therapeutics as good as vaccines for tularemia 71
Table 3.7: Developmental therapeutics as good as vaccines for smallpox 73
Table 3.8: Developmental therapeutics as good as vaccines for VHF 76
Table 3.9: Developmental therapeutics as good as vaccines for botulism 78
Table 3.10: Developmental therapeutics as good as vaccines for ricin 80
Table 3.11: Developmental therapeutics as good as vaccines for staphylococcal enterotoxins 81
Table 3.12: Developmental therapeutics as good as vaccines for brucella 82
Table 3.13: Developmental therapeutics as good as vaccines for glanders 84
Table 3.14: Developmental therapeutics as good as vaccines for melioidosis 85
Table 3.15: Developmental therapeutics as good as vaccines for Q heat 86
For More inform greatfully hit :
http://www.aarkstore.com/reports/The-Future-of-the-Biodefense-Industry-Regulation-funding-opportunities-company-profiles-34851.html
